ArticleIndian journal of psychological medicine2026
Orexinergic Dysregulation in Major Depressive Disorder: Insights from a Prospective Cohort Study Evaluating MADRS, PSQI, and MoCA Scores.
Article in Indian journal of psychological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Major depressive disorder (MDD) is a complex psychiatric condition characterized by affective, cognitive, and somatic symptoms. Disturbances in sleep and cognition are common yet underexplored features of MDD. Orexin, a hypothalamic neuropeptide, plays key roles in arousal, sleep-wake regulation, and cognition. This was a prospective, observational study with longitudinal follow-up investigating the correlation between serum orexin- Methods: A total of 113 patients with MDD and 60 age- and sex-matched healthy controls were assessed in this study. Patients were followed up after 6-12 weeks of antidepressant therapy. Symptom severity, sleep quality, and cognitive status were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS), the Pittsburgh Sleep Quality Index (PSQI), and the Montreal Cognitive Assessment (MoCA), respectively. Serum orexin- Results: The median (Q1-Q3) serum orexin levels in patients and healthy controls were 192.6 (183.2-209.3) pg/mL and 207.4 (203.8-218.7) pg/mL, respectively, with a statistically significant difference ( Conclusions: Serum orexin-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.